Insulet (NSDQ:PODD) is moving its corporate headquarters to Billerica, Mass., 9 minutes away from the company’s current home in Bedford, Mass.
Insulet
Diabetes: Insulet to hire 20 new sales reps as pediatric pump sales soar
Neuro Kinetics appoints new CFO | Personnel Moves
Neuro Kinetics appointed Michael Saporito as its new CFO.
Saporito joins the Pittsburgh-based medical device company after years with LifeVest, which he helped turn around before the company was bought out by Zoll Medical.
Deals: Insulet, Amgen team up for biotech drug infusion
Insulet misses Q3 expectations, tightens 2013 sales guidance
Insulet appoints 1st medical director | Personnel Moves
Insulet (NSDQ:PODD) said it named Dr. Howard Zisser, the former clinical director of the Sansum Diabetes Research Institute, as its 1st medical director.
Considered a leader in diabetes research, Zisser will be involved with a variety of clinical research projects and serve as a medical liaison between Insulet and government leaders, the FDA, and healthcare organizations, Bedford, Mass.-based Insulet said.
Diabetes: Insulet inks $10M settlement deal with Medtronic
UPDATE: Insulet slides on disputed report of increased adverse events, customer complaints
UPDATED Sept. 25 at 11:15 a.m. with Jefferies report on reporting change for adverse events involving OmniPod
SEC dings Deerfield Capital Management $2M for short-selling violations
China probes medtech pricing | Wall Street Beat
The Chinese Commerce Ministry’s anti-monopoly bureau is looking for information on pricing and operations at medical device makers within the country as well as from around the world, according to a Reuters report.
Local sources told the new service that concerns about local corruption and price-fixing may have spurred the survey, but a deputy director at the China Assn. for Medial Devices Industry told reporters that there hadn’t been word of any official investigations into the sector.